Physician profile
Chris E Hayner
NPI 1164466371
$2,032.07
in general payments reported to CMS, 2019-2025
18 companies · $780 in 2025
The $780 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.80 · 2020: $48.50 · 2021: $65.11 · 2022: $274 · 2023: $529 · 2024: $288 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.36 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $647.70 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $256.71 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $202.90 | 2022-2025 | Dupixent |
| Electromed, INC. | $143.74 | 2022-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.10 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $116.39 | 2020-2025 | Breztri, Tezspire, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $90.71 | 2022-2023 | Glassia |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Insmed, INC. | $79.29 | 2025 | Arikayce |
| Viz.Ai, INC. | $66.04 | 2022 | |
| Grifols USA, LLC | $39.45 | 2023-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $32.24 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $29.99 | 2024 | Tyvaso |
| Viatris Specialty LLC | $23.52 | 2025 | Yupelri |
| Vertex Pharmaceuticals Incorporated | $20.70 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $18.53 | 2019 | |
| Masimo Corporation | $18.43 | 2025 | Set and Rainbow Set |
| Teva Pharmaceuticals USA, INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Hayner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.